Topical compositions for the eye comprising a .beta.-cyclodextrin derivative and a therapeutic agent
OwnerJonathan C. Javitt, Norman B. Javitt +1inventors
InventorsJonathan C. Javitt, Norman B. Javitt, Peter McDonnell
Life of this patent
Estimating the term…
Abstract
A topical composition comprising an amount of a carbonic anhydrase inhibitor and an amount of .beta.-cyclodextrin derivative effective in increasing the bioavailability of the carbonic anhydrase inhibitor when coadministered topically to the eye.
Claims29
An ophthalmic eye drop dispenser comprising a topical, ophthalmic composition comprising an ophthalmically effective amount of carbonic anhydrase inhibitor and an amount of amorphous .beta.-cyclodextrin effective in increasing the bioavailability of the carbonic anhydrase inhibitor when coadministered topically to the eye.
An ophthalmic eye drop dispenser comprising a topical, ophthalmic composition comprising an ophthalmically effective amount of carbonic anhydrase inhibitor and an amount of amorphous .beta.-cyclodextrin effective in increasing the solubility of the carbonic anhydrase inhibitor in the composition in comparison to its solubility in the absence of the amorphous .beta.-cyclodextrin.
A method of treating an eye disorder treatable by administering a carbonic anhydrase inhibitor, comprising topically administering to an eye in need of such treatment a topical, ophthalmic composition comprising an ophthalmically effective amount of carbonic anhydrase inhibitor and an amount of amorphous .beta.-cyclodextrin effective in increasing the bioavailability of the carbonic anhydrase inhibitor when topically administered to the eye.
A topical ophthalmic composition comprising an ophthalmically effective amount of carbonic anhydrase inhibitor and 40-60 w/v % of amorphous .beta.-cyclodextrin, said amount of .beta.-cyclodextrin being effective to increase the bioavailability of the carbonic anhydrase inhibitor upon topical administration.
A method of treating an eye disorder treatable by administering to an eye in need of such treatment an ophthalmically active agent, comprising topically administering to the eye a topical, ophthalmic composition comprising an effective amount of ophthalmically active agent effective in treating said disorder and an amount of hydroxypropyl-.beta.-cyclodextrin effective in increasing the bioavailability of the ophthalmically active agent when topically administered to the eye.
A topical ophthalmic applicator comprising a topical, ophthalmic composition comprising an ophthalmically effective amount of carbonic anhydrase inhibitor and an amount of amorphous .beta.-cyclodextrin effective in increasing the bioavailability of the carbonic anhydrase inhibitor when coadministered topically to the eye.
Dependencies are inferred from the claim text.